Teachers Retirement System of The State of Kentucky Has $6.01 Million Stock Position in Insulet Co. (NASDAQ:PODD)

Teachers Retirement System of The State of Kentucky boosted its position in Insulet Co. (NASDAQ:PODD) by 23.9% in the 1st quarter, HoldingsChannel reports. The firm owned 35,035 shares of the medical instruments supplier’s stock after acquiring an additional 6,754 shares during the period. Teachers Retirement System of The State of Kentucky’s holdings in Insulet were worth $6,006,000 as of its most recent filing with the SEC.

Several other hedge funds have also bought and sold shares of the company. Beck Bode LLC raised its holdings in Insulet by 41.3% in the 1st quarter. Beck Bode LLC now owns 69,761 shares of the medical instruments supplier’s stock valued at $11,957,000 after acquiring an additional 20,373 shares during the period. Swedbank AB bought a new position in Insulet in the 1st quarter valued at about $6,903,000. Plato Investment Management Ltd raised its holdings in Insulet by 1,574.0% in the 1st quarter. Plato Investment Management Ltd now owns 6,060 shares of the medical instruments supplier’s stock valued at $1,039,000 after acquiring an additional 5,698 shares during the period. iA Global Asset Management Inc. bought a new position in Insulet in the 1st quarter valued at about $105,000. Finally, Tidal Investments LLC raised its holdings in Insulet by 58.8% in the 1st quarter. Tidal Investments LLC now owns 4,064 shares of the medical instruments supplier’s stock valued at $697,000 after acquiring an additional 1,504 shares during the period.

Insulet Price Performance

NASDAQ:PODD traded down $0.80 during mid-day trading on Friday, reaching $196.45. The stock had a trading volume of 843,823 shares, compared to its average volume of 622,718. The stock has a 50-day simple moving average of $194.74 and a two-hundred day simple moving average of $184.32. The stock has a market capitalization of $13.76 billion, a PE ratio of 59.53, a P/E/G ratio of 3.55 and a beta of 1.16. The company has a debt-to-equity ratio of 1.72, a current ratio of 3.74 and a quick ratio of 2.75. Insulet Co. has a 12 month low of $125.82 and a 12 month high of $269.33.

Insulet (NASDAQ:PODD) last announced its quarterly earnings data on Thursday, May 9th. The medical instruments supplier reported $0.73 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.39 by $0.34. The business had revenue of $441.70 million for the quarter, compared to analysts’ expectations of $424.05 million. Insulet had a net margin of 13.14% and a return on equity of 34.06%. The firm’s quarterly revenue was up 23.3% compared to the same quarter last year. During the same period last year, the firm posted $0.23 earnings per share. On average, equities analysts anticipate that Insulet Co. will post 3.11 earnings per share for the current year.

Insider Transactions at Insulet

In other Insulet news, Director Timothy J. Scannell sold 3,300 shares of the stock in a transaction dated Tuesday, May 28th. The stock was sold at an average price of $180.90, for a total value of $596,970.00. Following the completion of the transaction, the director now directly owns 42,586 shares in the company, valued at $7,703,807.40. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. In other Insulet news, SVP Mark N. Field sold 2,131 shares of the company’s stock in a transaction that occurred on Monday, June 10th. The shares were sold at an average price of $190.43, for a total value of $405,806.33. Following the completion of the transaction, the senior vice president now directly owns 14,375 shares in the company, valued at approximately $2,737,431.25. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. Also, Director Timothy J. Scannell sold 3,300 shares of the company’s stock in a transaction that occurred on Tuesday, May 28th. The shares were sold at an average price of $180.90, for a total transaction of $596,970.00. Following the completion of the transaction, the director now owns 42,586 shares of the company’s stock, valued at $7,703,807.40. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 13,931 shares of company stock worth $2,636,286. Corporate insiders own 0.47% of the company’s stock.

Wall Street Analyst Weigh In

Several research analysts have weighed in on PODD shares. Jefferies Financial Group increased their price target on shares of Insulet from $255.00 to $260.00 and gave the company a “buy” rating in a report on Friday, May 10th. Redburn Atlantic assumed coverage on shares of Insulet in a report on Thursday, May 30th. They issued a “buy” rating and a $235.00 price target on the stock. Raymond James lowered their target price on shares of Insulet from $218.00 to $213.00 and set an “outperform” rating on the stock in a report on Friday, May 10th. Canaccord Genuity Group reaffirmed a “buy” rating and set a $234.00 target price on shares of Insulet in a report on Tuesday, July 23rd. Finally, OTR Global reaffirmed a “mixed” rating on shares of Insulet in a report on Monday, June 10th. Four equities research analysts have rated the stock with a hold rating and fifteen have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, Insulet currently has a consensus rating of “Moderate Buy” and an average price target of $239.18.

About Insulet

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.